الفهرس 
ContentsOnly 14 pages are availabe for public view
 |  | from | 124 |  |  |
| | | from | 124 | | |
Abstract
Two approaches have been recognio fr cli— nieal trcatment of Parkinsons diseases The first was based upon augmenting the brain dopamine (V) content, i.e. by imiking the dopa1nine receptors, whereas the second was dependant upon the use of antioholinergic drugs, designated as antitremor agents.
Alhough L—dopa (111), the imrncd:Late precursor of dopaiinc (V)1 was the pioneer cccipound to be applied as .opamineric agent, yet is us was proved disadvantageous because of the serious side ffeots elicited.
In. an effort to explore drugs possessing dopa— minergic activity with fairly acceptable side effects; apomorphine (XVI), which was knowi. to incorporate a dopamLa moiety wtbhin its struotire, was identified to be an effeotive candidate in this rospect. This discovery had initiated studies for the structure— activity relationships of m.any aporaophine derivatives as well as sorne of its simplified structural analogs.